A diabetes drug from Johnson & Johnson (NYSE:JNJ) has shown promise in reducing blood-sugar levels in patients receiving insulin therapy.
The drug, canagliflozin, developed to treat people with type-2 diabetes, also produced benefits for patients facing an elevated possibility of heart trouble, Reuters noted.
Patients taking the drug in an 18-week study of more than 1,700 subjects experienced significant reductions in blood glucose, blood pressure and weight. More than 50% of the patients in the study had a history of cardiac issues.
At the end of the study, patients taking canagliflozin saw their A1C blood glucose levels fall by 0.65% and 0.73%, depending on what dosage of the drug the consumed. A control group taking a placebo showed no change in blood glucose levels.
Johnson & Johnson has submitted the drug to European and American regulators, hoping to obtain approval for its first diabetes treatment.
Researchers noted that some patients displayed indications of liver problems while on canagliflozin, but said the indications did not constitute a safety issue.
Shares of Johnson & Johnson slipped fractionally in Tuesday trading.